We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$9.44B
1-Year Est. Return
157.3%
This Fund
S&P 500
This Quarter
Est. Return
-9.11%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$1.68B
AUM Growth
-$184M
(-9.9%)
Cap. Flow
+$113M
Cap. Flow
% of AUM
6.73%
Top 10 Holdings %
Top 10 Hldgs %
74.63%
Holding
34
New
9
Increased
4
Reduced
5
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
|
+$72.6M |
| 2 |
Travere Therapeutics
TVTX
|
+$65.9M |
| 3 |
Rhythm Pharmaceuticals
RYTM
|
+$33M |
| 4 |
Solid Biosciences
SLDB
|
+$14.2M |
| 5 |
Kodiak Sciences
KOD
|
+$13.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$67.4M |
| 2 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
+$28.3M |
| 3 |
Axsome Therapeutics
AXSM
|
+$17.4M |
| 4 |
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
|
+$14.8M |
| 5 |
X4 Pharmaceuticals
XFOR
|
+$5.06M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DVAX
26
DELISTED
Dynavax Technologies
DVAX
| $8.46M | 0.5% |
+2,365,912
| New | +$9.17M |
|
|
IGMS
27
DELISTED
IGM Biosciences
IGMS
| $8.28M | 0.49% |
+466,368
| New | +$9.41M |
|
|
28
X4 Pharmaceuticals
XFOR
$377M
| $6.08M | 0.36% |
15,937
-12,776
| -44% | -$5.06M |
|
|
ODT
29
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| $5.21M | 0.31% |
200,000
| – | – |
|
|
CMRX
30
DELISTED
Chimerix, Inc.
CMRX
| $4.19M | 0.25% |
+1,782,202
| New | +$5.15M |
|
|
EPIX
31
DELISTED
ESSA Pharma
EPIX
| $3.37M | 0.2% |
+1,000,000
| New | +$2.47M |
|
32
Senseonics Holdings Inc
SENS
$254M
| $2.7M | 0.16% |
+136,364
| New | +$3.3M |
|
|
GTHX
33
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| – | – |
-483,990
| Closed | -$14.8M |
|
|
SWAV
34
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| – | – |
-495,608
| Closed | -$28.3M |
|
Similar funds
RCMNY
SCM
SIM
NPT
AC
PVI
WPL
BAMF
RA Capital Management's Q3 2019 Portfolio in Review
As of Q3 2019, RA Capital Management held 34 positions worth $1.68B, down 9.9% from $1.86B the previous quarter. Its ten largest holdings account for 75% of the portfolio.
RA Capital Management deployed $113M of net new capital in Q3 2019, opening 9 new positions and adding to 4 existing holdings. Its largest new stake was Satsuma Pharmaceuticals, Inc. Common Stock: 4,681,858 shares worth $70.3M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier.
On the sell side, the largest reduction was Zogenix, Inc., an estimated $67.4M trimmed.
- RA Capital Management's largest Q3 2019 buy was Satsuma Pharmaceuticals, Inc. Common Stock: 4,681,858 shares worth $70.3M.
- RA Capital Management added most to Rhythm Pharmaceuticals in Q3 2019, an estimated $33M increase.
- RA Capital Management's biggest Q3 2019 reduction was Zogenix, Inc., cutting an estimated $67.4M.
- RA Capital Management fully exited Shockwave Medical, Inc. Common Stock in Q3 2019, selling an estimated $28.3M.
- RA Capital Management's ten largest holdings make up 75% of its $1.68B portfolio in Q3 2019.
- RA Capital Management opened 9 new positions and closed 2 in Q3 2019.
- RA Capital Management's portfolio value fell 9.9% quarter-over-quarter to $1.68B.
Based on RA Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.